Table S1. Example of original extracted data by study (for early <30 days outcomes) prior to collation seen in Tables 4 and 5 in main text.
| Primary author | Mortality (%) | Cardiac death (%) | PPM (%) | AF (%) | CVA (%) | TBB (%) | Bleeding (%) | TP (%) | Explants (%) | Endo-carditis (%) | Hemolysis (%) | Valve thrombosis (%) | SVD | Severe PVL (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shrestha | 3.4 | 1.9 | 6.0 | NR | 1.6 | 2.3 | NR | NR | 1.4 | 0.3 | 0.5 | 0 | 0 | 1.4 |
| Laufer | 1.7 | 1.7 | 6.6 | NR | 3.8 | 0.3 | 7.7 | NR | 1.4 | 0 | 0 | 0 | 0 | 0.7 |
| Andreas | 0.8 | NR | 8.6 | NR | 3.6 | 0 | 0.2 | NR | 1.0 | 0 | NR | 0 | 0 | NR |
| Glauber | 0.4 | 0.2 | 3.3 | NR | 2.3 | 0.2 | 1.9 | 0.4 | 0.6 | 0 | NR | 0 | NR | 0.2 |
| Weighted estimate (95% CI) | 1.4 (0.4–3.1) | 1.1 (0.2–2.7) | 6.0 (4.0–8.4) | – | 2.7 (1.7–3.8) | 0.5 (0–1.9) | 2.4 (0.03–7.6) | – | 1.1 (0.6–1.6) | – | – | – | – | 0.7 (0.1–1.6) |
PPM, permanent pacemaker; AF, atrial fibrillation; CVA, cerebrovascular accident; TBB, thromboembolism; TP, Tamponade; SVD, structural valve deterioration/degeneration; PVL, paravalvular leakage; NR, not reported.